Pharmacokinetics of recombinant human growth hormone administered by cool.click™ 2, a new needle-free device, compared with subcutaneous administration using a conventional syringe and needle
2007

Needle-Free Growth Hormone Delivery Compared to Standard Injection

Sample size: 38 publication Evidence: high

Author Information

Author(s): Chris Brearley, Anthony Priestley, James Leighton-Scott, Michel Christen

Primary Institution: Serono International SA

Hypothesis

The study aims to assess the bioequivalence of recombinant human growth hormone administered by a new needle-free device compared to a standard needle and syringe.

Conclusion

The cool.click™ 2 device delivers r-hGH exposure that is bioequivalent to the conventional needle and syringe method.

Supporting Evidence

  • The pharmacokinetic parameters showed no significant difference between the two administration methods.
  • The new device was well tolerated by participants.
  • The study demonstrated that the new device could improve patient adherence to treatment.

Takeaway

This study shows that a new needle-free device for delivering growth hormone works just as well as using a regular needle, making it easier and less scary for patients.

Methodology

A randomized, two-period, two-sequence crossover study was conducted with 38 healthy volunteers to compare the pharmacokinetics of r-hGH administered by cool.click™ 2 and a standard syringe.

Limitations

The study was limited to healthy male volunteers aged 21-50, which may not represent the broader population of growth hormone deficiency patients.

Participant Demographics

Healthy male volunteers aged 21-50 with a BMI of 22-30 kg/m2.

Statistical Information

P-Value

0.002

Confidence Interval

90% CI for Cmax: 103.7–118.3; AUC0-inf: 97.1–110.0

Statistical Significance

p = 0.002

Digital Object Identifier (DOI)

10.1186/1472-6904-7-10

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication